Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease
-
- STATUS
- Recruiting
-
- End date
- Dec 11, 2023
-
- participants needed
- 16
-
- sponsor
- AvroBio
Summary
This is a multinational, open-label study to assess the safety and efficacy of AVR-RD-02 in approximately 8 to 16 subjects (male or female) who are 18 and 45 years of age and postpubertal at Screening with a confirmed diagnosis of Type 1 Gaucher disease (based on clinical phenotype, genotyping, and deficient GCase enzyme activity in whole blood).
Description
Five study periods (Screening, Baseline, Pre-transplant, Transplant, and Post-transplant Follow-up) comprise the study. During the Screening Period (up to 60 days), written informed consent will be obtained and the subject will complete other Screening procedures to confirm study eligibility. Once study eligibility is confirmed, subjects will enter the Baseline Period (up to 3 days) during which time assessments will be performed to establish pre-transplant baseline. Once baseline assessments are complete, the subject will enter the Pre-transplant Period (approximately 6 to 8 weeks) during which time mobilization, apheresis, AVR-RD-02 investigational product preparation and testing for release, conditioning regimen administration, and conditioning washout period will take place. Enzyme replacement therapy must be discontinued at least 2 weeks before the scheduled transplant day. Following completion of the Pre-transplant Period, the subject will enter the Transplant Period (1 day) during which AVR-RD-02 transplant will take place. After AVR-RD-02 transplant, the subject will enter the Post-transplant Follow-up Period (approximately 52 weeks) during which time periodic safety and efficacy assessments will be performed to assess measures of safety, engraftment, and clinical response post-transplant. During the post-transplant period, subjects will not receive ERT unless pre-specified laboratory and clinical criteria, which suggest the need for ERT initiation, are met.
Details
| Condition | Gaucher Disease |
|---|---|
| Treatment | AVR-RD-02 |
| Clinical Study Identifier | NCT04145037 |
| Sponsor | AvroBio |
| Last Modified on | 16 February 2022 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer